The Journal of Pharmacy and Bioallied Sciences is a premier open access publication that has been contributing to the fields of Pharmacy, Bioengineering, and Biochemistry since its establishment in India, under the esteemed Wolters Kluwer Medknow Publications. With the ISSN 0976-4879 and E-ISSN 0975-7406, this journal provides a platform for high-quality research articles, reviews, and clinical studies aimed at advancing knowledge and practice in the pharmaceutical and allied sciences. As a reflection of its academic stature, the journal holds a respectable categorization within the third and fourth quartiles in pertinent fields according to the latest metrics, with rankings that place it among prominent emerging research in pharmacology and biochemistry. Researchers and professionals are encouraged to access a wealth of knowledge freely, as the journal has been open access since 2010. The journal not only aims to foster innovative research but also strives to bridge the gap between pharmaceutical sciences and real-world applications, making it an essential resource for students, academics, and industry experts alike.

Pharmacy is a premier open-access journal published by MDPI, dedicated to advancing research in the dynamic field of pharmaceutical sciences. Since its inception in 2013, this journal has become a vital platform for disseminating novel findings, reviews, and insights related to drug development, pharmacokinetics, pharmaceutical technology, and clinical applications. With an E-ISSN of 2226-4787, Pharmacy prioritizes accessibility and visibility, allowing researchers, professionals, and students from around the globe to engage with cutting-edge research without barriers. The journal plays a crucial role in shaping pharmaceutical education and practice, fostering innovative ideas and collaborative approaches aimed at improving health outcomes. As part of the MDPI family, Pharmacy is committed to maintaining high-quality standards, ensuring that all published articles undergo rigorous peer review.

JOURNAL OF PHARMACY PRACTICE, published by SAGE PUBLICATIONS INC, is a vital resource for researchers, pharmacy practitioners, and students dedicated to advancing the pharmacological and pharmaceutical sciences. Established in 1988, the journal serves as a platform for original research, reviews, and critical analyses in the fields of pharmacy and pharmacology. With an impressive impact factor and a strong presence in the Q2 category in Pharmacy and Q3 in Pharmacology (medical) as of 2023, it reflects the journal's commitment to delivering high-quality scholarly content that addresses pressing issues in pharmacy practice and medication management. The journal is indexed in Scopus, ranking #154 out of 272 in the field of Medicine and Pharmacology, positioning it within the 43rd percentile. Although it currently does not offer open access options, it remains an essential publication for those seeking to stay updated on innovations and best practices in the pharmacy sector, making it an indispensable tool for academic and professional growth.

PHARMACIA is a distinguished open-access journal, published by PENSOFT PUBLISHERS, that has been a pivotal platform for advancing the field of pharmaceutical sciences since 2007. This journal, with ISSN 0428-0296 and E-ISSN 2603-557X, is based in Bulgaria and continues to publish high-quality research and reviews relevant to pharmacy, pharmacology, and toxicology. Recognized in the Q3 category for Pharmaceutical Sciences and Pharmacology (medical), as well as Q2 in Pharmacy according to the latest rankings, PHARMACIA is celebrated for its commitment to fostering knowledge dissemination and innovation in drug development, therapeutic approaches, and pharmacological research. With a Scopus rank of #17 in Pharmacy and recognition in various health professions, the journal attracts contributions from researchers, professionals, and students seeking to impact the pharmaceutical landscape. Its convenient open-access format ensures that articles are readily available to a global audience, encouraging collaboration and advancement in the life sciences.

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

SAUDI PHARMACEUTICAL JOURNAL, published by Elsevier, stands as a pivotal platform for scholarly communication within the realm of pharmaceutical sciences and pharmacology. With a commendable Q2 ranking in both Pharmaceutical Science and Pharmacology for 2023, this journal reflects a strong commitment to advancing scientific understanding and innovation. Open Access since 2009, the journal ensures that cutting-edge research is readily accessible to researchers, professionals, and students around the globe, fostering collaboration and knowledge sharing. Based in the Netherlands, the journal covers a wide scope of topics, contributing to a cumulative understanding of drug development, therapeutic strategies, and pharmaceutical education. With a significant presence in Scopus rankings—#57 in Pharmaceutical Science and #116 in Pharmacology—SAUDI PHARMACEUTICAL JOURNAL is a trusted resource for high-quality research that shapes the future of pharmaceutical sciences.

The Egyptian Pharmaceutical Journal, published by Wolters Kluwer Medknow Publications, stands as a vital resource for researchers and practitioners in the fields of pharmaceutical sciences and biotechnology. With an ISSN of 1687-4315 and E-ISSN of 2090-9853, this journal disseminates high-quality, peer-reviewed research that spans a wide array of topics including pharmacology, toxicology, and biochemistry. Despite its emerging status, as reflected in its current Q4 and Q3 quartile rankings across various categories, the journal plays a significant role in contributing to the academic dialogue and promoting innovative findings within the scientific community. Operating from India, the journal is committed to open access principles, ensuring that cutting-edge research is readily available to a global audience. As the journal continues to evolve from its 2019 to 2024 convergence period, it aims to further enhance its impact factor and broaden its scope in the interdisciplinary domains of pharmaceutical sciences. Whether you are a student exploring new frontiers or a seasoned researcher aiming to publish your findings, The Egyptian Pharmaceutical Journal remains a dynamic platform for advancement in your field.

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.